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LETTERS TO THE EDITOR
Long-Range Polymerase Chain Reaction for Speci¢c Full-Length
Ampli¢cation of the Human Keratin 14 Gene and Novel Keratin
14 Mutations in Epidermolysis Bullosa Simplex Patients
To the Editor:
Epidermolysis bullosa simplex (EBS) is an autosomal dominant
genetic skin disorder characterized by intraepidermal blistering
in response to mild physical trauma (Irvine and McLean, 1999).
In EBS, histologic and/or ultrastructural examination shows that
blistering occurs in the subnuclear cytoplasm of basal keratino-
cytes. The disorder can be subdivided into three subgroups de-
pending on the severity of the disease (Fine et al, 2000). The
EBS Dowling^Meara variant is the most severe variant with
widespread herpetiform blistering occurring within the ¢rst
week following birth. EBS Weber^Cockayne and EBS K˛bner
are milder forms of the disease where blistering is mainly loca-
lized to hands and feet. These forms of EBS are predominantly
caused by dominant-negative mutations, either missense or small
in-frame insertion^deletion mutations, in keratin 5 (K5) or K14
(Irvine and McLean, 1999). K5 and K14 polymerize to form the
intermediate ¢lament cytoskeleton of basal keratinocytes (Cou-
lombe and Omary, 2002). Structural weakening of this cytoskele-
tal system due to genetic mutations leads to fragility of basal
keratinocytes and therefore to hereditary skin blistering.
Mutation detection strategies for the K5 gene (KRT5) have
been described previously (Stephens et al, 1997; Whittock et al,
2000) but reliable mutation detection for the K14 gene (KRT14)
has proved to be more di⁄cult due to the presence of pseudo-
genes. One intron-containing pseudogene for K14 was reported
some time ago (Savtchenko et al, 1988); however, a more recent
survey of the emerging human genome data reported a second
partial pseudogene for K14 (Hesse et al, 2001). Mutational analysis
for K14 has previously been carried out using cDNA prepared
from skin biopsies or, more often, using pairs of polymerase
chain reaction (PCR) primers speci¢c for each exon of the func-
tional K14 gene (Chen et al, 1995; Mˇller et al, 1998; Shemanko
et al, 1998). Another strategy based on long-range ampli¢cation
of KRT14 and its pseudogene(s) involved restriction digestion of
genomic DNA (Hut et al, 2000). Here, we present a robust long-
range PCR method that speci¢cally ampli¢es the whole of the
K14 gene from genomic DNA.This allows sequencing of the en-
tire K14 gene from one PCR product using internal primers.
Using this method, we have identi¢ed three novel mutations in
K14 in EBS patients.
The reported K14 genomic sequence was used for homology
searching of the April 2002 version of the human genome se-
quence, via the UCSC website (http://genome.ucsc.edu). This re-
vealed two full-length intron-containing pseudogenes, which
were 94.9% and 94.8% identical to the functional gene. This was
consistent with the recent survey of keratin genes in the emer-
ging genome data (Hesse et al, 2001). These pseudogenes appear
to be located several megabases of DNA centromeric to the type
I keratin gene cluster on chromosome 17, assuming the current
genome assembly to be correct in this region (data not shown).
Alignment of the £anking regions of the K14 gene and its two
pseudogenes identi¢ed a number of places where primers might
be placed to speci¢cally amplify the functional gene. A number
of these were tested for ease of ampli¢cation and speci¢city, of
which the following primers and conditions were found to be
optimal. Forward primer K14spf2 (50 -ATT TCA GGG ATG
GGA CAG AC-30) and reverse primer K14spr2 (50 -GAG GGG
ATC TTC CAG TGG GAT CT-30) were used in 50 ml reactions
containing 100 ng genomic DNA, 2 mg per ml each primer,
250 mM of each dNTP and Expand LongTemplate PCR system,
0.2 ml Long Template enzyme mix, and Long Template reaction
bu¡er 1 (Roche Diagnostics, Lewes, U.K.). A ‘‘touchdown’’ PCR
program was used. The PCRs were initially denatured at 941C
for 2 min followed by 941C 30 s, 621C 30 s, 721C 4 min for two
cycles; then 941C 30 s, 601C 30 s, 721C 4 min for two cycles;
941C 30 s, 591C 30 s, 721C 4 min for 25 cycles; followed by
721C for 5 min. PCRwas performed in a computer-controlled
ThermoHybaid MBS thermocycler with heated lid, without use
of mineral oil. Simulated tube control with a 50 ml volume set-
ting were used for the PCR program within the MBS software.
The resultant 5099 bp PCR product (Fig 1) spans all of the
KRT14 gene including 624 bp upstream of the initiation codon
ATG of K14 and 69 bp downstream of the TGA codon. Using
this method we identi¢ed three novel EBS mutations found at
either end of the K14 gene, by sequencing with internal primers
(Fig 1). Two mutations, R148C and S128del, were found in the
1A domain, encoded by exon 1 of KRT14. The third mutation,
R416P, was found in the helix termination motif at the end of
the 2B domain, encoded by exon 6 (Fig 1). The mutations were
con¢rmed by tried and tested PCRs speci¢c for the individual
exons concerned, exons 1 and 6 (Shemanko et al, 1998). The same
mutations were found by sequencing of these fragments (data
not shown). Mutation R148C creates a novel Bgl II site, S128del
ablates an Mnl I site, and R416P destroys an Fnu4H I site. All
three novel mutations were excluded from 50 normal ethnically
matched controls by the appropriate restriction digests (data
not shown). Mutations S128del and R416P are located in the he-
lix initiation and termination motifs of K14, respectively. These
are known mutation hotspots for EBS Dowling^Meara (Irvine
and McLean, 1999), consistent with the observed phenotypes of
these two patients. Mutation R148C is located in the second half
of the 1A domain, a known hotspot associated with milder phe-
notypes (Irvine and McLean, 1999), consistent with the diagnosis
of EBS Weber^Cockayne in the patient examined here. Clinical
details of these patients will be reported elsewhere.
Avoiding pseudogene ampli¢cation is a particular problem in
the molecular diagnosis of keratin disorders as many keratins have
multiple pseudogenes. A recent survey of the human genome re-
vealed that, of4250 intermediate ¢lament genes, about 75% are
keratin-related pseudogenes (Hesse et al, 2001). The problem is
particularly prominent in diagnosis of the two most common
types of pachyonychia congenita (PC), where the PC-1 pheno-
type is caused by mutations in K6a or K16 and the PC-2 variant
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is caused by mutations in K6b or K17. Humans possess at least six
homologous K6-like isogenes and/or pseudogenes (Takahashi et
al, 1995). K16 and K17 each have two pseudogenes (Troyanovsky
et al, 1992; Smith et al, 1999a). Over the last few years, we have
developed robust long-range PCR strategies to enable mutation
screening for all coding regions of the K6a, K16, and K17 genes
(Smith et al, 1999a; 1999b;Terrinoni et al, 2001), thus enabling mu-
tation detection and prenatal diagnosis based on genomic DNA.
Similarly, the long-range PCR strategy described here is suitable
for detection of mutations in all exons of the K14 gene, circum-
venting the need for enzyme digestion of PCR fragments or ca-
libration of speci¢c PCR for each of the individual exons. A
further advantage of this system is that it may detect larger het-
erozygous genomic deletions, say involving one or two exons,
that would be missed by PCR of individual exons. For example,
a homozygous 1163 bp intragenic deletion mutation was recently
reported in the ECM1 gene in a lipoid proteinosis family (Hamada
et al, 2002). A similar mutation would be missed in heterozygotes
by PCRof individual exons but would be detected by the meth-
od described here. Therefore, the long-range PCR method
should be considered for other genes where there is no particular
pseudogene problem but where a group of patients exists that
lack mutations. The only drawback that we have observed in ap-
plication of this methodology is that DNA samples that are par-
tially degraded can be more di⁄cult to amplify for obvious
reasons; however, peripheral blood lymphocyte DNA and
mouthwash DNA samples prepared in our laboratory by a stan-
dard high-salt extraction method generally work well.
In conclusion, the method described here should ease the
molecular diagnosis of EBS in the routine laboratory and perhaps
identify mutations missed by other strategies.
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Figure1. Long-range PCR to detect novel KRT14 mutations in
EBS patients. (a) PCR ampli¢cation of a 5.1 kb genomic DNA fragment
containing all exons and £anking regions of the functional KRT14 gene
analyzed on a 1% agarose/0.5 x TBE gel. Lane 1, molecular weight markers
(Hyperladder I, Bioline, London, U.K.), the arrow indicates 5 kb marker;
lane 2, typical PCR product ampli¢ed from a normal control DNA; lane
3, negative control showing no ampli¢cation. (b)(g) Direct sequencing
of KRT14 long-range PCR products with internal primers. Sequences
shown in panels b, c, d, and f were generated with sequencing primer
K14p8 (þ strand, 50 GGG GGAGCC TATGGGTTG GGG 30). Sequences
shown in panels e and g were generated with sequencing primer K14pm20
(þ strand, 50 CAG AGC GGC AAG AGC GAG AT 30). (b) Normal con-
trol sequence from exon 1, showing codons 126^130. A CCT repeat is pre-
sent in this region of the gene (boxed). (c) The same region as shown in (b)
derived from a patient with EBS Dowling^Meara, showing heterozygous
deletion mutation 383delCCT, predicting the amino acid change 128delS
in the helix initiation motif of the K14 polypeptide. The ¢rst CCT repeat
is unchanged (boxed) but the second CCT is deleted, leading to overlapping
sequence traces. This mutation occurs in a known mutation hotspot asso-
ciated with severe EBS phenotypes. (d) Normal control sequence from
exon 1, showing codons 146^150. (e) Normal control sequence from exon
6, showing codons 414^418. (f) The same region as shown in (d) derived
from a patient with EBS Weber^Cockayne, showing heterozygous transi-
tion mutation 442C-T, predicting the amino acid change R148C in the
latter half of the 1A domain of the K14 polypeptide. This is a known muta-
tion hotspot associated with milder EBS phenotypes. (g) The same region
as shown in (e) derived from a patient with EBS Dowling^Meara, showing
heterozygous transversion mutation 1247G-C, predicting the amino acid
change R416P in the helix termination motif of the K14 polypeptide. This
is a known mutation hotspot associated with more severe EBS phenotypes.
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